Company Presentation
December 2020
Allena Pharmaceuticals, Inc.
These slides, and the accompanying presentation, contain forward-looking statements and information. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate,"
"believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions
are intended to identify forward-looking statements. All forward-looking statements are based on estimates and assumptions by our management that, although we believe them to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected, including those risks and uncertainties that are described under the heading "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
This presentation also contains estimates and other statistical data made by independent parties and us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.
2
Our Purpose
Making a Difference for Patients with Rare Metabolic and Kidney Disorders
3
Pioneering Technology in
Oral Enzyme Therapeutics | Formulation | Proprietary |
Technology | development | |
approach |
Therapeutic Platform | |
Oral Enzyme | GI MOA |
Therapeutic candidates that degrade a specific metabolite
Reloxaliase ALLN-346
Non-absorbed
Reduces potential for
adverse events
Leverage GI
tract as
"auxiliary kidney"
4
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Allena Pharmaceuticals Inc. published this content on 30 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 November 2020 13:02:02 UTC